EU firms facing new requirements for orphan drug designation
This article was originally published in Scrip
Executive Summary
Companies developing products for rare diseases in the EU could be facing changes to the requirements for gaining orphan drug designation, after the European Commission announced that it planned to review the criteria for showing that a new product has a "significant benefit" over existing treatments.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.